EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Obstacles and improvement strategies for CAR-T cell therapy in solid tumors

Zhihao Luo, Qian Hu, Meng Ren, Li Wang, Qingshuang Zou, Xiaosha Wen, Shang Chen, Quan Liu, Dixian Luo, Zifen Guo

Discover Oncology · 10.02.2026 · 17 (1)

DOI: 10.1007/s12672-026-04473-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Discover Oncology, online erschienen am 10.02.2026. Verfasst von Zhihao Luo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan Province, P. R. China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shenzhen Natural Science Foundation Project, National Key R&D Program of China, Newly introduced discipline leader fund project in Nanshan District of Shenzhen City.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CAR-T cell therapy, which genetically modifies a patient’s T cells to express chimeric antigen receptors (CARs), has shown remarkable efficacy in treating blood cancers. However, its application to solid tumors is hindered by challenges such as inadequate tumor infiltration, an immunosuppressive microenvironment, and metabolic obstacles. This review explores potential targets for CAR-T cells in solid tumors and examines innovative strategies to enhance their tumor penetration, survival, and cytotoxicity. These include advanced CAR designs, combination therapies, and methods to improve CAR-T cell function amidst metabolic competition. As research and technology progress, CAR-T therapy holds promise as a viable option for solid tumor treatment, with future efforts emphasizing interdisciplinary collaboration to unlock its full potential.

Schlagwörter

Stichwörter der Autor:innen

Antigen escapeCAR-TImmunosuppressive microenvironmentImmunotherapyMetabolic competitionSolid tumor

Autor:innen und Institutionen

  • Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan Province, P. R. China.
  • School of Nursing, University of South China, Hengyang, Hunan Province, P. R. China.
  • Laboratory Medicine Center, Shenzhen Luohu Hospital Group, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen University, Shenzhen, Guangdong Province, P. R. China.
  • Hunan Provincial University Key Laboratory of the Fundamental and Clinical Research on Functional Nucleic Acid, Changsha Medical University, Changsha, 410219, China.
  • Laboratory Medicine Center, The sixth Affiliated Hospital of Shenzhen University (Nanshan District People's Hospital), Shenzhen, China.
  • Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan Province, P. R. China. guozifen76@163.com.

Förderung

  • Shenzhen Natural Science Foundation Project
  • National Key R&D Program of China
  • Newly introduced discipline leader fund project in Nanshan District of Shenzhen City
  • General Projects of the National Natural Science Foundation of China
  • Guangdong Provincial Clinical Research Center for Laboratory Medicine

Zitieren

APA

Luo, Z., Hu, Q., Ren, M., Wang, L., Zou, Q., Wen, X., Chen, S., Liu, Q., Luo, D., & Guo, Z. (2026). Obstacles and improvement strategies for CAR-T cell therapy in solid tumors. Discover Oncology, 17(1). https://doi.org/10.1007/s12672-026-04473-8

Vancouver

Luo Z, Hu Q, Ren M, Wang L, Zou Q, Wen X, et al. Obstacles and improvement strategies for CAR-T cell therapy in solid tumors. Discover Oncology. 2026;17(1). doi:10.1007/s12672-026-04473-8

BibTeX
@article{Luo2026,
  author = {Luo, Zhihao and Hu, Qian and Ren, Meng and Wang, Li and Zou, Qingshuang and Wen, Xiaosha and Chen, Shang and Liu, Quan and Luo, Dixian and Guo, Zifen},
  title = {Obstacles and improvement strategies for CAR-T cell therapy in solid tumors},
  journal = {Discover Oncology},
  year = {2026},
  volume = {17},
  number = {1},
  doi = {10.1007/s12672-026-04473-8}
}
Kostenlos starten →